Advertisement

Topics

Opdivo and Tafinlar+Mekinst hailed in earlier melanoma treatment

06:39 EDT 11 Sep 2017 | pharmaphorum

Two new regimens look set to transform treatment to delay melanoma returning in patients after surgery. Results from Bristol-Myers Squibb’s Opdivo and Novartis' Tafinlar plus Mekinst were presented alongside each other this morning at ESMO in Ma...

Original Article: Opdivo and Tafinlar+Mekinst hailed in earlier melanoma treatment

NEXT ARTICLE

More From BioPortfolio on "Opdivo and Tafinlar+Mekinst hailed in earlier melanoma treatment"

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...